MANNKIND CORP Construction Payable, Current
MANNKIND CORP (MNKD) had Construction Payable, Current of $98.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Payables and Accruals
us-gaap:ConstructionPayableCurrent · last filed 2024-05-08
- 2024-03-31: Construction Payable, Current $98.00K.
- 2023-12-31: Construction Payable, Current $316.00K.
- 2023-09-30: Construction Payable, Current $173.00K.
- 2023-06-30: Construction Payable, Current $93.00K.
| Period end | Construction Payable, Current |
|---|---|
| 2024-03-31 | $98.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $316.00K 10-Q · filed 2024-05-08 |
| 2023-09-30 | $173.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $93.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $168.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $846.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.36M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $144.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.37M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $786.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $7.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.05M 10-Q · filed 2021-08-11 |
| 2015-12-31 | $238.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $19.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $42.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $579.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $1.34M 10-K · filed 2016-03-15 |
| 2014-09-30 | $2.74M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $2.81M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $370.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $342.00K 10-K · filed 2015-03-02 |
| 2013-09-30 | $226.00K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $2.66M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $3.75M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $3.88M 10-K · filed 2014-03-03 |
| 2012-09-30 | $2.54M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $2.10M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |